Collagen Innovation Shifts to Targeted Clinical Evidence for Healthy Ageing Applications

London, United Kingdom — 15 July 2024

The collagen market is entering a new phase, moving beyond established beauty-from-within and mobility applications. Demand is now focusing on healthy ageing and multifunctional nutrition solutions, requiring a deeper scientific foundation for product development. Innova Market Insights data confirms that 52% of consumers across Europe are incorporating more collagen into their diets, signalling sustained consumer interest. This trend has fueled a 17% annual growth rate in supplement and sports nutrition launches featuring collagen between July 2021 and June 2026.

Historically, skin, joint, and bone health have driven collagen product claims. However, the market now seeks more sophisticated formulations that address broader aspects of healthy ageing. This shift necessitates ingredient suppliers and brand owners to invest in targeted research and clinical trials, moving away from generic collagen claims towards specific peptide fractions with proven efficacy for particular physiological outcomes. Manufacturers must ensure their raw material procurement aligns with suppliers offering comprehensive scientific dossiers.

The emphasis on targeted applications and ingredient-specific science presents both an opportunity and a challenge. Brands that can demonstrate clinically validated benefits for novel applications, such as gut health or muscle maintenance in older adults, will gain a significant competitive edge. Conversely, those relying on broad, unsubstantiated claims risk market erosion as consumer scrutiny and regulatory expectations for substantiation increase. This evolution impacts reformulation cycles and requires closer collaboration between R&D, procurement, and marketing teams.

What this means for United Kingdom

UK brand owners must pivot product development towards clinically substantiated collagen ingredients, particularly for the expanding healthy ageing demographic. Investment in specific scientific evidence for product claims will be crucial to maintain MHRA and ASA compliance. Manufacturers should scrutinise supplier data sheets for ingredient-specific clinical trials, ensuring new formulations offer demonstrable efficacy beyond standard skin and joint benefits. The rising consumer demand for collagen presents an opportunity for premiumisation through validated, targeted applications, potentially commanding higher margins if supported by robust science. Retailers like Holland & Barrett will increasingly favour differentiated, evidence-backed products, influencing listing decisions and promotional support.

This trend is being actively addressed by UK manufacturing partners including Supplement Factory.